Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

Authors: Jennifer M. Giltnane, Katherine E. Hutchinson, Thomas Stricker, Luigi Formisano, Christian D. Young, Mónica V. Estrada, Mellissa J. Nixon, Liping Du, Violeta Sánchez, Paula I. González-Ericsson, María G. Kuba, Melinda E. Sanders, Xinmeng Jasmine Mu, Eliezer M. Van Allen, Nikhil Wagle, Ingrid A. Mayer, Vandana G. Abramson, Henry Gómez, Monica Rizzo, Weiyi Toy, Sarat Chandarlapaty, Erica L. Mayer, Jason Christiansen, Danielle Murphy, Kerry Fitzgerald, Kai Wang, Jeffrey S. Ross, Vincent A. Miller, P. J. Stephens, Roman Yelensky, Levi A. Garraway, Yu Shyr, Ingrid M. Meszoely, Justin M. Balko, Carlos L. Arteaga - Science Translational Medicine 2017 cited by 124

fusion transcripts and increased expression of gene signatures indicative of enhanced E2F-mediated transcription and cell cycle processes in cancers with high Ki67. These data suggest that short-term preoperative estrogen deprivation followed by genomic profiling can be used to identify druggable alterations that may cause intrinsic endocrine therapy resistance.